Dexcom, Inc.
$35.57B- Market cap
- $33.17B
- Debt
- +$3.32B
- Cash
- −$917.70M
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $33.17B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: DXCM stock price at discount vs CTVA $87.90 current versus $114.77 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTVA's multiple
Implied fair value · at DXCM's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXCM FY 2025 (ended Dec 31, 2025) · CTVA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Capital structure 96% equity / 4% debt · EV / Revenue 3.26x · EV / EBITDA 19.07x
CTVA carries the larger enterprise value at $56.67B against $35.57B; CTVA trades on the lower EV / Revenue multiple (3.26x vs 7.63x); CTVA on the lower EV / EBITDA (19.07x vs 26.75x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DEXCOM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Corteva, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.21x
0.11x
Net debt / EBITDA
Leverage against operating earnings
1.81x
-0.66x
Cash and equivalents
Liquid reserves on the balance sheet
$917.70M
$4.53B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
DXCM vs ABT
Medtronic plc
DXCM vs MDT
BECTON DICKINSON & CO
DXCM vs BDX
MOSAIC CO
DXCM vs MOS
CF Industries Holdings, Inc.
DXCM vs CF
Archer-Daniels-Midland Co
DXCM vs ADM
INTERNATIONAL FLAVORS & FRAGRANCES INC
DXCM vs IFF
Bunge Global SA
DXCM vs BG
Ingredion Inc
DXCM vs INGR
$3.32B
$2.58B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.